SGMT Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

7.895

Open

7.770

VWAP

7.74

Vol

1.34M

Mkt Cap

474.87M

Low

7.640

Amount

10.38M

EV/EBITDA(TTM)

Total Shares

61.75M

373.42M

EV/OCF(TTM)

P/S(TTM)

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

Events Timeline

(ET)

2026-05-12

07:40:00

Sagimet Plans to Initiate Phase 3 Acne Trial in H2 2026

News

5.0

06-23Newsfilter

Sagimet Biosciences Announces Employee Stock Option Grants

5.0

06-23Yahoo Finance

Sagimet Biosciences Announces Employee Stock Option Inducement Grant

8.5

05-12Newsfilter

Sagimet Biosciences Secures $175M Equity Financing for Acne Trials

4.0

05-05moomoo

SAGIMET BIOSCIENCES INC: CANACCORD GENUITY INCREASES TARGET PRICE FROM $28 TO $49

8.5

04-27Fool

Sagimet Biosciences Announces New Drug Trial Plans

8.5

04-27stocktwits

Sagimet Plans Phase 3 Trial Launch for Denifanstat in 2026

10 Analyst Rating

Wall Street analysts forecast SGMT stock price to rise

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

27.00

High

37.00

Current: 0.000

Low

8.00

Averages

27.00

High

37.00

Citizens

Outperform

NULL

downgrade

$35 -> $12

AI Analysis

2026-05-19

Reason

Citizens

Price Target

$35 -> $12

AI Analysis

2026-05-19

downgrade

Outperform

NULL

Reason

Citizens lowered the firm's price target on Sagimet Biosciences to $12 from $35 and keeps an Outperform rating on the shares. Sagimet Biosciences is advancing denifanstat into a Phase 3 acne trial in 2H26 with pivotal data expected by year-end 2027, while next-generation FASN inhibitor TVB-3567 provides additional clinical and intellectual property upside, supporting a strategic shift into a large, under-innovated acne market with blockbuster revenue potential, the analyst tells investors in a research note.

Clear Street

Buy

downgrade

$37 -> $28

2026-05-13

Reason

Clear Street

Price Target

$37 -> $28

2026-05-13

downgrade

Buy

Reason

Clear Street lowered the firm's price target on Sagimet Biosciences to $28 from $37 and keeps a Buy rating on the shares. The firm is adjusting its model following the company's recent strategic shift to focus on acne vs. MASH, with a planned phase 3 initiation of denifanstat in moderate to severe acne expected in the second half of FY26, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SGMT

Unlock Now

Valuation Metrics

The current forward P/E ratio for Sagimet Biosciences Inc (SGMT.O) is 0.00, compared to its 5-year average forward P/E of -2.64. For a more detailed relative valuation and DCF analysis to assess Sagimet Biosciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.64

Current PE

0.00

Overvalued PE

-1.07

Undervalued PE

-4.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.21

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.48

Undervalued EV/EBITDA

-0.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

23.09

Current PS

60.19

Overvalued PS

221.37

Undervalued PS

-175.19

Financials

AI Analysis

Annual

Quarterly

Whales Holding SGMT

Affinity Asset Advisors, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Sagimet Biosciences Inc (SGMT) stock price today?

The current price of SGMT is 7.69 USD — it has decreased -0.65

What is Sagimet Biosciences Inc (SGMT)'s business?

What is the price predicton of SGMT Stock?

Wall Street analysts forecast SGMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMT is27.00 USD with a low forecast of 8.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.